Lymphocyte function-associated antigen 1 - Intercellular adhesion molecule 1 interaction (LFA-1/ICAM-1)

The interaction between Lymphocyte Function-associated Antigen 1 (LFA-1) and Intercellular Adhesion Molecule 1 (ICAM-1) is a fundamental process in the immune system that mediates the adhesion and migration of leukocytes (1.2.1, 1.5.2). LFA-1 is a heterodimeric integrin (alpha-L beta-2) primarily expressed on T cells and other white blood cells, while ICAM-1 is a transmembrane glycoprotein of the immunoglobulin superfamily expressed on endothelial cells, epithelial cells, and antigen-presenting cells (1.1.3, 1.5.1). This interaction is crucial for the firm adhesion of T cells to the vascular endothelium, enabling their extravasation into tissues, and is a key component of the immunological synapse required for T-cell activation and cytokine release (1.2.1, 1.4.4). In pathological states, the LFA-1/ICAM-1 pathway is often upregulated, contributing to chronic inflammation in diseases such as dry eye disease, psoriasis, and rheumatoid arthritis, as well as facilitating cancer cell metastasis (1.2.3, 1.5.1). Therapeutic targeting of this interaction, through small molecule antagonists like lifitegrast or monoclonal antibodies like efalizumab, aims to disrupt the inflammatory cycle by preventing T-cell recruitment and activation (1.3.4, 1.4.2). While effective, systemic inhibition has been associated with significant safety concerns, including progressive multifocal leukoencephalopathy, leading to a preference for localized or topical delivery in certain indications (1.3.4, 1.6.2).

Other names

CD11a/CD18 - CD54 interactionIntegrin alpha-L beta-2 - Intercellular adhesion molecule 1 interactionLFA-1/ICAM-1 complexLeukocyte function-associated antigen 1 - Intercellular adhesion molecule 1 interaction

Drugs targeting this interaction typically act as competitive antagonists or steric inhibitors that block the binding of the LFA-1 I-domain on T cells to the Ig-like domains of ICAM-1 on endothelial or antigen-presenting cells, thereby preventing T-cell recruitment, activation, and the subsequent inflammatory cascade (1.2.1, 1.3.1, 1.4.4).